Highlights from GSK Symposia at ERS 2020
INTREPID RESULTS: Investigation of Trelegy Effectiveness: Usual Practice Design.
Speaker: Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK
Real World Evidence in COPD - Symposium Recordings
- Devices – The Critical Link Between the Molecule and Treatment
Speaker: Professor Paul Jones PhD, FRCP, FERS. Medical Expert, GSK Emeritus Professor of Respiratory Medicine, St George’s, University of London UK.
- Treatment in the Real World
Speaker: Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK.
- Improving symptoms of COPD
Speaker: Professor Francois Maltais, Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada
COPD Treatment - Symposium Recordings
- Is there a key target in COPD?
Speaker: Professor Alberto Papi, Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy
- Reducing symptoms
Speaker: Professor Claus Vogelmeier, MD, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany.
- COPD treatment: targeting mortality
Speaker: Professor MeiLan Han, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
- Importance of preventing exacerbations
Speaker: Professor Alice M. Turner, University Hospitals Birmingham NHS Foundation Trust, and Institute of Applied Health Research, University of Birmingham, UK
Trelegy, Anoro, Relvar, Incruse, ELIPTA are registered trademark of the GlaxoSmithKline group of companies
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.